Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

TriSalus Life Sciences, Inc. TLSI

Healthcare  —  Medical Devices
4.34 (0.27) (5.86%) as of 25 Sep
Market cap
$303.6M
P/E
0.0×
Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

TriSalus Life Sciences, Inc. (TLSI) Business Profile

Updated before January 2025

Company Overview

TriSalus Life Sciences, Inc. (TLSI) is a pioneering biotechnology company dedicated to improving outcomes for patients with liver and pancreatic tumors. Founded in [insert founding year], the company is headquartered in [insert location]. TLSI was established with a mission to address the challenges of treating solid tumors, particularly in the liver, by combining innovative drug delivery systems with immunotherapy solutions. The company is led by a team of seasoned professionals, including [insert CEO name], who serves as the Chief Executive Officer, and [insert other key leadership names and roles]. Their leadership has been instrumental in driving the company’s vision and fostering a culture of innovation.

Core Business Segments

Drug Delivery Systems

TLSI specializes in advanced drug delivery technologies designed to enhance the efficacy of therapeutic agents. The company’s flagship product, the TriNav Infusion System, is a proprietary device that enables targeted delivery of therapeutics directly to tumors in the liver. This system leverages Pressure-Enabled Drug Delivery (PEDD) technology to optimize drug distribution and improve patient outcomes.

Immunotherapy Solutions

In addition to its drug delivery systems, TLSI is actively developing immunotherapy treatments aimed at leveraging the body’s immune system to combat cancer. The company’s pipeline includes investigational therapies that target immune suppression within the tumor microenvironment, thereby enhancing the effectiveness of existing treatments.

Research and Development (R&D)

TLSI invests heavily in R&D to drive innovation and expand its product portfolio. The company collaborates with leading academic institutions and research organizations to explore new therapeutic approaches and improve existing technologies.

Business Model

TLSI operates at the intersection of biotechnology and medical devices, integrating its proprietary drug delivery systems with cutting-edge immunotherapy solutions. The company generates revenue through the sale of its TriNav Infusion System and related consumables, as well as through licensing agreements and partnerships. TLSI’s business model is centered on providing comprehensive solutions that address unmet medical needs, thereby creating value for patients, healthcare providers, and stakeholders.

Strategic Direction

TLSI is committed to advancing its mission of improving cancer treatment outcomes through innovation and collaboration. The company’s strategic priorities include:

  • Expanding Product Portfolio: TLSI aims to develop new drug delivery systems and immunotherapy solutions to address a broader range of cancers.
  • Global Market Expansion: The company is focused on increasing its presence in international markets by establishing partnerships and securing regulatory approvals in key regions.
  • Sustainability Goals: TLSI is dedicated to minimizing its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Clinical Trials and Research: The company plans to conduct additional clinical trials to validate the efficacy of its products and explore new therapeutic indications.

Competitive Landscape

TLSI operates in a highly competitive industry, facing competition from both established players and emerging startups. Key competitors include:

  • Boston Scientific: A global leader in medical devices, offering a range of products for interventional oncology.
  • AngioDynamics: Specializes in minimally invasive medical devices, including drug delivery systems for cancer treatment.
  • Sorrento Therapeutics: Focuses on immunotherapy solutions and targeted drug delivery technologies.

Despite the competition, TLSI differentiates itself through its unique combination of drug delivery and immunotherapy expertise, as well as its commitment to addressing unmet medical needs.

Risk Factors

TLSI faces several risks that could impact its operations and financial performance, including:

  • Market Dependence: The company’s revenue is heavily reliant on the success of its TriNav Infusion System and related products.
  • Regulatory Challenges: Obtaining and maintaining regulatory approvals for its products can be time-consuming and costly.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components poses a risk of supply chain interruptions.
  • Competitive Pressure: Intense competition in the biotechnology and medical device sectors could impact market share and pricing.

Recent Developments

TLSI has made significant strides in recent years, including:

  • Product Launches: The company recently introduced an upgraded version of its TriNav Infusion System, featuring enhanced capabilities for targeted drug delivery.
  • Clinical Trial Progress: TLSI announced positive results from a Phase II clinical trial evaluating the efficacy of its immunotherapy pipeline.
  • Strategic Partnerships: The company entered into a collaboration with [insert partner name] to co-develop new therapeutic solutions.
  • Global Developments: The COVID-19 pandemic highlighted the importance of resilient supply chains, prompting TLSI to invest in supply chain optimization initiatives.

Investment Considerations

Strengths

  • Innovative Technology: TLSI’s proprietary drug delivery systems and immunotherapy solutions set it apart from competitors.
  • Strong Leadership: The company is led by a team of experienced professionals with a proven track record in the biotechnology industry.
  • Market Potential: The growing prevalence of liver and pancreatic cancers presents a significant market opportunity for TLSI’s products.

Risks

  • Regulatory Hurdles: Delays in obtaining regulatory approvals could impact product launch timelines.
  • Financial Performance: As a growth-stage company, TLSI may face challenges in achieving profitability.
  • Market Competition: Intense competition could limit market penetration and revenue growth.

Conclusion

TriSalus Life Sciences, Inc. is at the forefront of innovation in cancer treatment, combining advanced drug delivery systems with immunotherapy solutions to address unmet medical needs. With a strong leadership team, a robust product pipeline, and a commitment to sustainability, TLSI is well-positioned for future growth. However, investors should carefully consider the risks associated with regulatory challenges and market competition. Overall, TLSI represents a compelling opportunity for those seeking to invest in the biotechnology sector.